Amivantamab Plus Lazertinib Extends Second-Line PFS in EGFR-Mutant Advanced NSCLC

Firmonertinib 160 mg Demonstrates Efficacy in EGFR-Mutated NSCLC With Leptomeningeal Mets

September 24, 2026

AMIGO-1 Trial Meets 18-Month PFS End Point With Frontline Amivantamab Triplet in EGFR+ NSCLC Infographic

September 23, 2026

Osimertinib Plus Gefitinib Suppresses Acquired EGFR Resistance Mutations in First-Line NSCLC Infographic

September 23, 2026

Early FLAURA2 Data Show Osimertinib-Chemotherapy Benefit Holds Regardless of Baseline TP53 Status in EGFR+ NSCLC

September 23, 2026